Participating Faculty: The Evidence for Semaglutide 2.4 mg in Obesity From a Managed Care PerspectiveDecember 14th 2022
Increasing Clinical Awareness of Obesity as a Serious, Chronic, Relapsing, and Treatable DiseaseByEthan Lazarus, MD,Shiara Ortiz-Pujols, MD, MPHDecember 14th 2022
Patient Well-being and the Clinical and Economic Burdens Associated With Obesity in the United StatesByDanielle C. Massie, PharmD,Anastassia Amaro, MD,Michael Kaplan, DODecember 14th 2022
A Review of Current Guidelines for the Treatment of ObesityByMarc-André Cornier, MDDecember 14th 2022
Semaglutide 2.4-mg Injection as a Novel Approach for Chronic Weight ManagementByJanine Kyrillos, MDDecember 14th 2022
Managed Care Considerations of Weight Management Interventions for ObesityByAnastassia Amaro, MD,Michael Kaplan, DO,Danielle C. Massie, PharmDDecember 14th 2022
